Evidence map›Paper›PMID 26140241›Full record

ArticleOncoimmunology2015

Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.

Tomomi Toubai, Hou Guoqing, Corrine Rossi, Nathan Mathewson, Katherine Oravecz-Wilson, Emily Cummings, Julia Wu, Yaping Sun, Sung Choi, Pavan Reddy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Tomomi ToubaiDepartment of Internal Medicine; University of Michigan Comprehensive Cancer Center ; Ann Arbor, MI USA.
Hou GuoqingDepartment of Pediatrics and Communicable Diseases; University of Michigan Medical School ; Ann Arbor, MI USA.
Corrine RossiDepartment of Internal Medicine; University of Michigan Comprehensive Cancer Center ; Ann Arbor, MI USA.
Nathan MathewsonDepartment of Internal Medicine; University of Michigan Comprehensive Cancer Center ; Ann Arbor, MI USA.
Katherine Oravecz-WilsonDepartment of Internal Medicine; University of Michigan Comprehensive Cancer Center ; Ann Arbor, MI USA.
Emily CummingsDepartment of Internal Medicine; University of Michigan Comprehensive Cancer Center ; Ann Arbor, MI USA.
Julia WuDepartment of Internal Medicine; University of Michigan Comprehensive Cancer Center ; Ann Arbor, MI USA.
Yaping SunDepartment of Internal Medicine; University of Michigan Comprehensive Cancer Center ; Ann Arbor, MI USA.
Sung ChoiDepartment of Pediatrics and Communicable Diseases; University of Michigan Medical School ; Ann Arbor, MI USA.
Pavan ReddyDepartment of Internal Medicine; University of Michigan Comprehensive Cancer Center ; Ann Arbor, MI USA.
Ann Arbor Center for Independent Living · USUniversity of Michigan–Ann Arbor · US

Funding

MICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3M
Targeting antigen presentation to enhance GVL responses after Bone Marrow TransplR01HL090775 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI REDDY, PAVAN · 2008 to 2016
$3.4M
NHLBI NIH HHS R01 HL090775NIGMS NIH HHS T32 GM007863
6 · The paper itself

Abstract

The graft-versus-leukemia (GVL) effect following allogeneic hematopoietic stem cell transplantation (allo-HCT) is critical for its curative potential. Hwever, GVL is tightly linked to graft-versus-host disease (GVHD). Among hematological malignancies, acute lymphoblastic leukemia (ALL) is the most resistant to GVL, although the reasons for this remain poorly understood. Clinical studies have identified alterations in Ikaros (Ik) transcription factor as the major marker associated with poor outcomes in ALL. We have shown that the absence of Ik in professional host-derived hematopoietic antigen-presenting cells (APCs) exacerbates GVHD. However, whether

Indexed as

51Cr, Chromium-51ALL, acute lymphoblastic leukemiaAllo-HCT, allogeneic hematopoietic stem cell transplantationantigen-presenting cellsAPC, allophycocyaninAPCs, antigen-presenting cellsBC, blast crisisBLI, bioluminescence imagingBM, bone marrowBMDCs, bone marrow derived dendritic cellsBMT, bone marrow transplantationbone marrow transplantationCML, chronic myeloid leukemiaCRT, calreticulinCTL, cytotoxic T cellDCs, dendritic cellsFACS, Fluorescence-activated cell sortingFBS, fatal bovine serumFITC, fluorescein isothiocyanategraft-versus-leukemiaGVHD, graft-versus-host-diseaseGVL, graft-versus-leukemiaHCT, hematopoietic stem cell transplantationICAM-1, intracellular adhesion molecule 1IkarosIk DN, Ikaros dominant negativeIk, Ikarosluc+, luciferase+mAbs, monoclonal antibodiesMACS, magnetic- activated cell sortingMBL-2, moloney-murine sarcoma virus-induced MBL-2 lymphoma cellsmCRT, murine calreticulinMHC, major histocompatibility complexMiHAs, multiple minor histocompatibility antigensMLR, mixed lymphocyte reactionPBS, phosphate buffered salinePE, phycoerythrinSIRP-α, signal regulatory protein αTCD-BM, T cell depleted bone marrowTregs, regulatory T cellsTSA, tumor specific antigenUCUCA, University Committee on Use and Care of AnimalsWT, wild-type

Identifiers

PMID26140241
PMCPMC4485841
OpenAlexW1494470742

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.